Evidence map›Paper›PMID 36193202›Full record

ArticleJournal of oncology2022

On the Core Prescriptions and Their Mechanisms of Traditional Chinese Medicine in Hepatitis B, Liver Cirrhosis, and Liver Cancer Treatment.

Zhendong Wang, Yong Zhang, Qiuyun Zhang, Qiang Ao, Changyong Luo, Bochuan Wang, Chen Bai, Xueyi Ge, Yuhan Wang, Jing Wang and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Biology · 2024
    Article
  6. The Role and Mechanism ofMolecules (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Zhendong WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.ORCID https://orcid.org/0000-0002-1500-3269
Yong ZhangLiver Disease Branch, Shandong Hospital of Traditional Chinese Medicine, Jinan, China.
Qiuyun ZhangCapital Medical University, Beijing, China.
Qiang AoBeijing Tcmages Pharmaceutical Co., Ltd., Beijing, China.
Changyong LuoDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.ORCID https://orcid.org/0000-0002-4342-6947
Bochuan WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Chen BaiSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xueyi GeShandong University of Traditional Chinese Medicine, Jinan, China.
Yuhan WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Jing WangDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Ying QianCapital Medical University, Beijing, China.
He YuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.ORCID https://orcid.org/0000-0001-5727-4924
Xiaohong GuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.ORCID https://orcid.org/0000-0001-8361-9455
Beijing University of Chinese Medicine · CNCapital Medical University · CNJining Traditional Chinese Medicine Hospital · CNShandong University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As a frequent cause of death in cancer patients, liver cancer usually occurs in hepatitis B and cirrhosis. In China, Chinese people have been using traditional Chinese medicine (TCM) in treating various chronic liver diseases, which could effectively improve the symptoms and slow down the progression of liver diseases. However, due to the complexity rules of TCM prescription, their action mechanisms are still not clearly understood, which may affect the popularization of effective prescriptions. This study aims to identify the core TCM herbs in the treatment of hepatitis B, liver cirrhosis, and liver cancer so as to clarify the mechanism of action of the core herb networks. Methods: There were 1,673 prescriptions for chronic liver diseases collected in this study, of which 854 were hepatic B prescriptions, 530 were for liver cirrhosis, and 289 were for liver cancer. The basic characteristics of herbal medicine were firstly explained via descriptive analysis, then the core prescriptions of herbal medicine were analyzed through association rule, and finally, the mechanism of core prescriptions was explored with the help of systematic network pharmacology and by applying such databases as TCMIP, HERB, OMIM, GeneCards, KEGG, and software like RStudio and Cytoscape. Results: The rule of the core prescriptions in these cases was characterized by the application of herbs with both cold and warm properties, in which bitter herbs with cold property took priority. Tonifying deficiency, clearing heat, and activating blood circulations to remove stasis were common treatment principles for the three liver diseases. Turmeric Root Tuber (YuJin), White Peony Root (BaiShao), Bupleurum (ChaiHu), Salvia miltiorrhiza (DanShen), and Astragali Radix (HuangQi) were prescribed the most in hepatitis B treatment to invigorate the spleen and soothe the liver. Astragali Radix (HuangQi), Tuckahoe (FuLing), Atractylodis Macrocephalae Rhizoma (BaiZhu), Fructus Polygoni Orientalis (ShuiHongHuaZi), and Curcumae Rhizome (EZhu) were most frequently applied in liver cirrhosis treatment to replenish qi and activate blood. Conclusion: Three core prescriptions for hepatitis B, liver cirrhosis, and liver cancer treatment were identified, which acted mainly through signal transduction and immune system pathways to regulate immunity and cell growth and participate in inflammation inhibition, in which liver cancer prescription regulated more pathways, especially more nervous system-related pathways than the other two.

Identifiers

PMID36193202
PMCPMC9525786
OpenAlexW4297023665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.